crizotinib
Selected indexed studies
- Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. (J Thorac Oncol, 2021) [PMID:34537440]
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. (N Engl J Med, 2013) [PMID:23724913]
- Crizotinib. (Recent Results Cancer Res, 2018) [PMID:30069759]
_Worker-drafted node — pending editorial review._
Connections
crizotinib is a side effect of
Sources
- Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer. (2022) pubmed
- Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. (2021) pubmed
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. (2013) pubmed
- Crizotinib. (2018) pubmed
- Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. (2021) pubmed
- Inhibition of PRKAA/AMPK (Ser485/491) phosphorylation by crizotinib induces cardiotoxicity via perturbing autophagosome-lysosome fusion. (2024) pubmed
- Disturbing Cholesterol/Sphingolipid Metabolism by Squalene Epoxidase Arises Crizotinib Hepatotoxicity. (2025) pubmed
- Crizotinib Versus Chemotherapy on ALK-positive NSCLC: A Systematic Review of Efficacy and Safety. (2019) pubmed
- Crizotinib resistance: implications for therapeutic strategies. (2016) pubmed
- Neoadjuvant Crizotinib for ALK Re-arranged NSCLC? (2019) pubmed